×
S&P 500   3,819.23 (-0.06%)
DOW   31,065.77 (+0.38%)
QQQ   284.35 (+0.29%)
AAPL   139.96 (+1.83%)
MSFT   261.58 (+1.99%)
META   163.40 (+1.69%)
GOOGL   2,225.41 (-0.66%)
AMZN   109.38 (+1.84%)
TSLA   681.03 (-2.43%)
NVDA   154.56 (-3.29%)
NIO   21.65 (-3.18%)
BABA   115.46 (-1.11%)
AMD   77.65 (-3.87%)
MU   55.75 (-3.65%)
CGC   3.52 (-2.49%)
T   20.99 (+1.84%)
GE   63.59 (-3.48%)
F   11.52 (-2.46%)
DIS   95.79 (-0.14%)
AMC   13.55 (+1.27%)
PFE   51.23 (+1.13%)
PYPL   71.29 (-0.74%)
NFLX   177.33 (-1.26%)
S&P 500   3,819.23 (-0.06%)
DOW   31,065.77 (+0.38%)
QQQ   284.35 (+0.29%)
AAPL   139.96 (+1.83%)
MSFT   261.58 (+1.99%)
META   163.40 (+1.69%)
GOOGL   2,225.41 (-0.66%)
AMZN   109.38 (+1.84%)
TSLA   681.03 (-2.43%)
NVDA   154.56 (-3.29%)
NIO   21.65 (-3.18%)
BABA   115.46 (-1.11%)
AMD   77.65 (-3.87%)
MU   55.75 (-3.65%)
CGC   3.52 (-2.49%)
T   20.99 (+1.84%)
GE   63.59 (-3.48%)
F   11.52 (-2.46%)
DIS   95.79 (-0.14%)
AMC   13.55 (+1.27%)
PFE   51.23 (+1.13%)
PYPL   71.29 (-0.74%)
NFLX   177.33 (-1.26%)
S&P 500   3,819.23 (-0.06%)
DOW   31,065.77 (+0.38%)
QQQ   284.35 (+0.29%)
AAPL   139.96 (+1.83%)
MSFT   261.58 (+1.99%)
META   163.40 (+1.69%)
GOOGL   2,225.41 (-0.66%)
AMZN   109.38 (+1.84%)
TSLA   681.03 (-2.43%)
NVDA   154.56 (-3.29%)
NIO   21.65 (-3.18%)
BABA   115.46 (-1.11%)
AMD   77.65 (-3.87%)
MU   55.75 (-3.65%)
CGC   3.52 (-2.49%)
T   20.99 (+1.84%)
GE   63.59 (-3.48%)
F   11.52 (-2.46%)
DIS   95.79 (-0.14%)
AMC   13.55 (+1.27%)
PFE   51.23 (+1.13%)
PYPL   71.29 (-0.74%)
NFLX   177.33 (-1.26%)
S&P 500   3,819.23 (-0.06%)
DOW   31,065.77 (+0.38%)
QQQ   284.35 (+0.29%)
AAPL   139.96 (+1.83%)
MSFT   261.58 (+1.99%)
META   163.40 (+1.69%)
GOOGL   2,225.41 (-0.66%)
AMZN   109.38 (+1.84%)
TSLA   681.03 (-2.43%)
NVDA   154.56 (-3.29%)
NIO   21.65 (-3.18%)
BABA   115.46 (-1.11%)
AMD   77.65 (-3.87%)
MU   55.75 (-3.65%)
CGC   3.52 (-2.49%)
T   20.99 (+1.84%)
GE   63.59 (-3.48%)
F   11.52 (-2.46%)
DIS   95.79 (-0.14%)
AMC   13.55 (+1.27%)
PFE   51.23 (+1.13%)
PYPL   71.29 (-0.74%)
NFLX   177.33 (-1.26%)
NASDAQ:EOLS

Evolus Stock Forecast, Price & News

$11.65
-0.22 (-1.85%)
(As of 06/29/2022 02:27 PM ET)
Add
Compare
Today's Range
$11.50
$11.82
50-Day Range
$10.22
$13.94
52-Week Range
$5.06
$14.34
Volume
7,380 shs
Average Volume
507,153 shs
Market Capitalization
$652.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.33
30 days | 90 days | 365 days | Advanced Chart

Receive EOLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter.

EOLS Stock Forecast (MarketRank)

Overall MarketRank

1.93 out of 5 stars

Medical Sector

670th out of 1,433 stocks

Pharmaceutical Preparations Industry

318th out of 685 stocks

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
Evolus logo

About Evolus (NASDAQ:EOLS)

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

EOLS Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EOLS
Fax
N/A
Employees
167
Year Founded
N/A

Company Calendar

Last Earnings
5/10/2022
Today
6/29/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$15.33
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+31.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83333333333333
Research Coverage
6 Analysts

Profitability

Net Income
$-46.81 million
Pretax Margin
-58.25%

Debt

Sales & Book Value

Annual Sales
$99.67 million
Book Value
$1.47 per share

Miscellaneous

Free Float
51,789,000
Market Cap
$652.97 million
Optionable
Optionable
Beta
2.07














Evolus Frequently Asked Questions

Should I buy or sell Evolus stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Evolus stock.
View analyst ratings for Evolus
or view top-rated stocks.

What is Evolus' stock price forecast for 2022?

6 Wall Street research analysts have issued 12-month target prices for Evolus' shares. Their EOLS stock forecasts range from $10.00 to $20.00. On average, they expect Evolus' share price to reach $15.33 in the next twelve months. This suggests a possible upside of 31.6% from the stock's current price.
View analysts' price targets for Evolus
or view top-rated stocks among Wall Street analysts.

How has Evolus' stock performed in 2022?

Evolus' stock was trading at $6.51 on January 1st, 2022. Since then, EOLS stock has increased by 79.0% and is now trading at $11.65.
View the best growth stocks for 2022 here
.

When is Evolus' next earnings date?

Evolus is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Evolus
.

How were Evolus' earnings last quarter?

Evolus, Inc. (NASDAQ:EOLS) announced its quarterly earnings data on Tuesday, May, 10th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.24. The business had revenue of $33.90 million for the quarter, compared to the consensus estimate of $29.83 million. Evolus had a negative net margin of 58.28% and a negative trailing twelve-month return on equity of 80.20%. The firm's revenue was up 177.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.16 earnings per share.
View Evolus' earnings history
.

What guidance has Evolus issued on next quarter's earnings?

Evolus issued an update on its FY 2022 earnings guidance on Tuesday, June, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $150.00 million-$150.00 million, compared to the consensus revenue estimate of $148.47 million.

Who are Evolus' key executives?

Evolus' management team includes the following people:
  • Mr. David Moatazedi, Pres, CEO & Director (Age 44, Pay $1.23M) (LinkedIn Profile)
  • Dr. Rui Avelar C.CFP, Dip.SportMed, M.D., Chief Medical Officer and Head of R&D (Age 60, Pay $660.08k)
  • Mr. David K. Erickson, VP of Investor Relations
  • Mr. Jeffrey J. Plumer, Gen. Counsel
  • Mr. Kurt Knab, VP of Sales
  • Ms. Crystal Muilenburg, Chief Marketing Officer (Age 42)
  • Ms. Jessica Novak, Sr. VP of HR

What is David Moatazedi's approval rating as Evolus' CEO?

1 employees have rated Evolus CEO David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among Evolus' employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Evolus own?

When did Evolus IPO?

(EOLS) raised $65 million in an initial public offering (IPO) on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

What is Evolus' stock symbol?

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Who are Evolus' major shareholders?

Evolus' stock is owned by a variety of retail and institutional investors. Top institutional investors include First Manhattan Co. (7.29%), BlackRock Inc. (3.93%), Vanguard Group Inc. (3.22%), Deerfield Management Company L.P. Series C (2.19%), AIGH Capital Management LLC (1.96%) and State Street Corp (1.24%). Company insiders that own Evolus stock include Alphaeon 1 Llc, Crystal Muilenburg, David Moatazedi, David N Gill, Lauren P Silvernail, Medytox Inc, Rui Avelar and Vikram Malik.
View institutional ownership trends for Evolus
.

Which institutional investors are selling Evolus stock?

EOLS stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Federated Hermes Inc., Group One Trading L.P., Charles Schwab Investment Management Inc., Simplex Trading LLC, BlackRock Inc., Prudential Financial Inc., and Northern Trust Corp. Company insiders that have sold Evolus company stock in the last two years include Alphaeon 1 Llc, Crystal Muilenburg, David Moatazedi, David N Gill, Lauren P Silvernail, Rui Avelar, and Vikram Malik.
View insider buying and selling activity for Evolus
or view top insider-selling stocks.

Which institutional investors are buying Evolus stock?

EOLS stock was acquired by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, AIGH Capital Management LLC, First Manhattan Co., Essex Investment Management Co. LLC, EAM Investors LLC, Worth Venture Partners LLC, Invesco Ltd., and Monarch Partners Asset Management LLC.
View insider buying and selling activity for Evolus
or or view top insider-buying stocks.

How do I buy shares of Evolus?

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evolus' stock price today?

One share of EOLS stock can currently be purchased for approximately $11.65.

How much money does Evolus make?

Evolus (NASDAQ:EOLS) has a market capitalization of $652.97 million and generates $99.67 million in revenue each year. The company earns $-46.81 million in net income (profit) each year or ($1.30) on an earnings per share basis.

How many employees does Evolus have?

Evolus employs 167 workers across the globe.

How can I contact Evolus?

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The official website for Evolus is www.evolus.com. The company can be reached via phone at (949) 284-4555 or via email at [email protected].

This page (NASDAQ:EOLS) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected]com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.